Q-omics provides the consensus-scored LINC02762 profile across patient tissues and cancer cell-line models. LINC02762 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC02762 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, LINC02762 RNA expression shows 17,458 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where LINC02762 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02762 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02762 survival associations across molecular data types. LINC02762 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02762 RNA expression–survival associations across cancer types. High LINC02762 expression shows unfavorable associations in HNSC, BRCA and BLCA, but favorable associations in KIRC, UCS and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC02762 RNA expression.
This table summarizes LINC02762 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02762. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02762 shows lower tumor expression in STAD and BLCA and higher tumor expression in KIRC, HNSC, KIRP and KICH. The KIRC box plot shows higher LINC02762 RNA expression in tumor versus normal tissue (log2 FC = +1.808, t-test p < 0.001).
This table shows molecular features associated with LINC02762 in patient tissues and cancer cell lines. In patient samples, LINC02762 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
